12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lenvatinib: Phase II data

Data from 93 evaluable patients with wild-type BRAF V600 tumors in cohort 1 of an open-label, international Phase II trial showed that once-daily 24 mg lenvatinib produced a clinical benefit rate (CBR) of 32%, including 8 partial responses. Median PFS was 3.7 months and median OS was 9.5 months. Toxicity led to dose reduction in 46%...

Read the full 270 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >